Evidence map›Paper›PMID 35524277›Full record

ReviewJournal of nanobiotechnology2022

Application of lipid nanovesicle drug delivery system in cancer immunotherapy.

Yinan Ding, Luhong Wang, Han Li, Fengqin Miao, Zhiyuan Zhang, Chunmei Hu, Weiping Yu, Qiusha Tang, Guoliang Shao

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 61 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Yinan DingMedical School of Southeast University, Nanjing, 210009, China.
Luhong WangMedical School of Southeast University, Nanjing, 210009, China.
Han LiDepartment of Tuberculosis, the Second Affiliated Hospital of Southeast University (the Second Hospital of Nanjing), Nanjing, 210009, China.
Fengqin MiaoMedical School of Southeast University, Nanjing, 210009, China.
Zhiyuan ZhangDepartment of Neurosurgery, Nanjing Jinling Hospital, Nanjing University, Nanjing, 210002, China.
Chunmei HuDepartment of Tuberculosis, the Second Affiliated Hospital of Southeast University (the Second Hospital of Nanjing), Nanjing, 210009, China.
Weiping YuMedical School of Southeast University, Nanjing, 210009, China. wpylg@hotmail.com.
Qiusha TangMedical School of Southeast University, Nanjing, 210009, China. panyixi-tqs@163.com.
Guoliang ShaoDepartment of Interventional Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China. shaogl@zjcc.org.cn.
Southeast University · CNNanjing General Hospital of Nanjing Military Command · CNNanjing Second Hospital · CNUniversity of Chinese Academy of Sciences · CN

Funding

the China Postdoctoral Science Foundation Funded Project 2018M630605the high-level talents (333 Project) of Jiangsu Province BRA2019024the Key Project Foundation of Jiangsu Health and Health Committee H2018114the Social Development Project of the Key Research and Development Plan of Jiangsu Provinc e BE2018606
6 · The paper itself

Abstract

Immunotherapy has gradually emerged as the most promising anticancer therapy. In addition to conventional anti-PD-1/PD-L1 therapy, anti-CTLA-4 therapy, CAR-T therapy, etc., immunotherapy can also be induced by stimulating the maturation of immune cells or inhibiting negative immune cells, regulating the tumor immune microenvironment and cancer vaccines. Lipid nanovesicle drug delivery system includes liposomes, cell membrane vesicles, bacterial outer membrane vesicles, extracellular vesicles and hybrid vesicles. Lipid nanovesicles can be used as functional vesicles for cancer immunotherapy, and can also be used as drug carriers to deliver immunotherapy drugs to the tumor site for cancer immunotherapy. Here, we review recent advances in five kinds of lipid nanovesicles in cancer immunotherapy and assess the clinical application prospects of various lipid nanovesicles, hoping to provide valuable information for clinical translation in the future.

Indexed as

ImmunotherapyNeoplasmsDrug Delivery SystemsHumansLipidsTumor MicroenvironmentLipidsBacterial outer membrane vesiclesCancer immunotherapyCell membrane vesiclesExtracellular vesiclesHybrid nanovesiclesLiposomesNanovesicles

Identifiers

PMID35524277
PMCPMC9073823
OpenAlexW4229033713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.